07
Mar
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2023 and key developments from 2022 Plant Investment LAS VEGAS, March 7, 2023 (Newswire.com) - Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, issued a letter to shareholders today from President, Chief Science Officer, and Director Dr. Andrea Small-Howard and Chairman and CEO John Poss summarizing key developments from 2022 and providing strategic plans for 2023. Full text of the shareholder letter follows. A MESSAGE FROM BOTH THE PRESIDENT AND THE CHAIRMAN OF GB SCIENCES, INC.To Our Shareholders: In 2022, Gb…